We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Thomas A. Peter
Thomas A. Peter
Products
PRODUCTS
Zimmer Biomet, Inc.
Thomas A. Peter
,
Suyang Qin
, and
Joseph R. Strelnik
Price:
$117.00
View
Sagami Manufacturers Sdn. Bhd.
Thomas A. Peter
Price:
$117.00
View
Beijing KES Biology Technology Co., Ltd.
Thomas A. Peter
Price:
$117.00
View
BTS S.p.A.
Thomas A. Peter
Price:
$117.00
View
BioPro, Inc.
Cynthia Li
and
Thomas A. Peter
Price:
$117.00
View
Signal Medical Corp.
Cynthia Li
and
Thomas A. Peter
Price:
$117.00
View
Terumo Cardiovascular Systems Corp.
Kimberly Lewandowski-Walker
,
Thomas A. Peter
, and
Sargum C. Sood
Price:
$117.00
View
Zimmer, Inc.
Thomas A. Peter
,
Sargum C. Sood
, and
Joseph R. Strelnik
Price:
$117.00
View
Excel Medical Products
Thomas A. Peter
Price:
$117.00
View
Zimmer, Inc.
Brian M. Campbell
,
Thomas A. Peter
, and
Sargum C. Sood
Price:
$117.00
View
View All Products by Thomas A. Peter
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More